Detailed disclosure is attached

Revenue DeclineExceptional ItemRelated Party TransactionsResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.6%1-day move

₹35.25

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-1.6-0.7-0.7+2.0+1.8-2.0-3.4+3.3——

Up moveDown movePending

AI summary

Gujarat Terce Laboratories reported annual revenue of Rs 4,747.27 lakhs for FY2026, down 5.4% from Rs 5,019.52 lakhs in FY2025. The company returned to profitability with PAT of Rs 220.17 lakhs compared to a loss of Rs 97.87 lakhs in the previous year. An exceptional item of Rs 45.39 lakhs was recorded due to one-time provision for employee benefits under new labour codes. Cash flow from operations remained positive at Rs 171.47 lakhs. The statutory auditor issued an unmodified (clean) opinion. The Board also re-appointed Mr. Aalap Prajapati as Managing Director & CEO for 5 years from October 2026.

Likely market impact

Revenue decline of 5.4% is a concern, but the company swung from net loss to net profit of Rs 220.17 lakhs, indicating operational recovery. The clean audit opinion is positive for investors. The re-appointment of the CEO for another 5-year term provides continuity.